Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial

OBJECTIVES: Innovative post‐remission therapies are needed to eliminate residual AML cells. DC vaccination is a promising strategy to induce anti‐leukaemic immune responses. METHODS: We conducted a first‐in‐human phase I study using TLR7/8‐matured DCs transfected with RNA encoding the two AML‐associ...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Transl Immunology
Auteurs principaux: Lichtenegger, Felix S, Schnorfeil, Frauke M, Rothe, Maurine, Deiser, Katrin, Altmann, Torben, Bücklein, Veit L, Köhnke, Thomas, Augsberger, Christian, Konstandin, Nikola P, Spiekermann, Karsten, Moosmann, Andreas, Boehm, Stephan, Boxberg, Melanie, Heemskerk, Mirjam HM, Goerlich, Dennis, Wittmann, Georg, Wagner, Beate, Hiddemann, Wolfgang, Schendel, Dolores J, Kvalheim, Gunnar, Bigalke, Iris, Subklewe, Marion
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053229/
https://ncbi.nlm.nih.gov/pubmed/32153780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1117
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires